Mirati Therapeutics, Inc., a clinical-stage oncology company, develops product candidates to address the genetic and immunological promoters of cancer in the United States. More Details
Excellent balance sheet and slightly overvalued.
Share Price & News
How has Mirati Therapeutics's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: MRTX is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 7% a week.
Volatility Over Time: MRTX's weekly volatility (7%) has been stable over the past year.
7 Day Return
1 Year Return
Return vs Industry: MRTX exceeded the US Biotechs industry which returned 19.7% over the past year.
Return vs Market: MRTX matched the US Market which returned 50.8% over the past year.
Long-Term Price Volatility Vs. Market
How volatile is Mirati Therapeutics's share price compared to the market and industry in the last 5 years?
Simply Wall St News
1 week ago | Simply Wall StShareholders May Not Be So Generous With Mirati Therapeutics, Inc.'s (NASDAQ:MRTX) CEO Compensation And Here's Why
4 weeks ago | Simply Wall StWe're Not Very Worried About Mirati Therapeutics' (NASDAQ:MRTX) Cash Burn Rate
2 months ago | Simply Wall StAnalysts Have Just Cut Their Mirati Therapeutics, Inc. (NASDAQ:MRTX) Revenue Estimates By 40%
Is Mirati Therapeutics undervalued compared to its fair value and its price relative to the market?
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: MRTX ($156.62) is trading below our estimate of fair value ($861.16)
Significantly Below Fair Value: MRTX is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: MRTX is unprofitable, so we can't compare its PE Ratio to the US Biotechs industry average.
PE vs Market: MRTX is unprofitable, so we can't compare its PE Ratio to the US market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate MRTX's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: MRTX is overvalued based on its PB Ratio (6.4x) compared to the US Biotechs industry average (3.3x).
How is Mirati Therapeutics forecast to perform in the next 1 to 3 years based on estimates from 10 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: MRTX is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: MRTX is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: MRTX is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: MRTX's revenue (76% per year) is forecast to grow faster than the US market (9% per year).
High Growth Revenue: MRTX's revenue (76% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: MRTX is forecast to be unprofitable in 3 years.
How has Mirati Therapeutics performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: MRTX is currently unprofitable.
Growing Profit Margin: MRTX is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: MRTX is unprofitable, and losses have increased over the past 5 years at a rate of 39.6% per year.
Accelerating Growth: Unable to compare MRTX's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: MRTX is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (1.6%).
Return on Equity
High ROE: MRTX has a negative Return on Equity (-32.31%), as it is currently unprofitable.
How is Mirati Therapeutics's financial position?
Financial Position Analysis
Short Term Liabilities: MRTX's short term assets ($1.3B) exceed its short term liabilities ($77.1M).
Long Term Liabilities: MRTX's short term assets ($1.3B) exceed its long term liabilities ($44.3M).
Debt to Equity History and Analysis
Debt Level: MRTX is debt free.
Reducing Debt: MRTX has not had any debt for past 5 years.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: MRTX has sufficient cash runway for more than 3 years based on its current free cash flow.
Forecast Cash Runway: Insufficient data to determine if MRTX has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.
What is Mirati Therapeutics's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate MRTX's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate MRTX's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if MRTX's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if MRTX's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of MRTX's dividend in 3 years as they are not forecast to pay a notable one for the US market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Chuck Baum (62 yo)
Dr. Charles M. Baum, M.D., Ph.D., also known as Chuck, serves as an Independent Director at BCTG Acquisition Corp since September 08, 2020. He serves as the Director at PMV Pharmaceuticals, Inc. since Apri...
CEO Compensation Analysis
Compensation vs Market: Chuck's total compensation ($USD11.75M) is above average for companies of similar size in the US market ($USD6.51M).
Compensation vs Earnings: Chuck's compensation has increased whilst the company is unprofitable.
Experienced Management: MRTX's management team is not considered experienced ( 1.3 years average tenure), which suggests a new team.
Experienced Board: MRTX's board of directors are considered experienced (4.7 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: MRTX insiders have only sold shares in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 17.9%.
Mirati Therapeutics, Inc.'s company bio, employee growth, exchange listings and data sources
- Name: Mirati Therapeutics, Inc.
- Ticker: MRTX
- Exchange: NasdaqGS
- Founded: 1995
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Market Cap: US$8.057b
- Shares outstanding: 51.44m
- Website: https://www.mirati.com
Number of Employees
- Mirati Therapeutics, Inc.
- 9393 Towne Centre Drive
- Suite 200
- San Diego
- United States
Mirati Therapeutics, Inc., a clinical-stage oncology company, develops product candidates to address the genetic and immunological promoters of cancer in the United States. The company develops MRTX849, a ...
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2021/05/16 23:21|
|End of Day Share Price||2021/05/14 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.